<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, June 10, 2020 (HealthDay News) — Low-dose aspirin significantly lowers cardiovascular disease (CVD) risk but increases the risk for bleeding, according to a review published online June 2 in the British Journal of Clinical Pharmacology<\/i>.<\/p>\n
Nicola Veronese, M.D., from the National Research Council in Padua, Italy, and colleagues conducted a systematic literature review to identify meta-analyses of observational studies and randomized controlled trials comparing low-dose aspirin to placebo or other treatments.<\/p>\n
Based on 67 meta-analyses, the researchers found evidence for aspirin use and an increased risk for upper gastrointestinal bleeding (relative risk [RR], 2.28). For low-dose aspirin, there was strong evidence for a lower risk for CVD in people without CVD (RR, 0.83) and in the general population (RR, 0.83). However, there was also a higher risk for major gastrointestinal (RR, 1.47) and intracranial bleeding (RR, 1.34) as well as major bleeding in people without CVD (RR, 1.62).<\/p>\n
“These risks and benefits need to be weighted in formal decision analysis to guide aspirin use in primary prevention,” the authors write.<\/p>\n
One study author disclosed financial ties to the pharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n